AstraZeneca takes $80 mln hit as U.S. spurns nasal flu vaccine

LONDON, June 23 (Reuters) - AstraZeneca said it

would take an $80 million writedown on stocks of its flu vaccine

Flumist Quadrivalent, which is sprayed into the nose, after U.S.

health authorities decided they would not use the product.

Read more